Fresh Versus Frozen Euploid Blastocyst Transfer Outcomes in Predicted High-Responders: Menopur in GNRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer - High Responder (Megaset-Hr) Trial Analysis

Heiser, Patrick W.; Crain, J.L.; Johnson, Lauren; Patrick, Jennifer L.; Foster, Eric D.; Sinha, Anshul; Elci, Okan U.; Daftary, Gaurang S.

doi:10.1016/j.fertnstert.2020.08.282

Fertility and Sterility

2020

DOI: 10.1016/j.fertnstert.2020.08.282

|View full text |Cite

Fresh Versus Frozen Euploid Blastocyst Transfer Outcomes in Predicted High-Responders: Menopur in GNRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer - High Responder (Megaset-Hr) Trial Analysis

Patrick W. Heiser

J.L. Crain

Lauren Johnson

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Evolution of Assisted Reproductive Technologies: A Modern Approach to Ovarian Stimulation

Whitehouse¹

2018

EMJ Repro Health

View full text Add to dashboard Cite

In celebration of the 40th anniversary of the first in vitro fertilisation (IVF) baby this year, the symposium focussed on the modern-day approach to ovarian stimulation (OS). Chairperson Prof Fauser welcomed delegates with a look at the key achievements related to OS in the context of assisted reproductive technologies (ART) over the past century. Treatments have evolved from the first crude preparations to the refined gonadotrophin products available for clinical use today. The theme of personalisation in OS was introduced by Dr Labarta, who looked at how we can use accurate biomarker measurements to assess ovarian reserve, predict ovarian response, and, therefore, personalise treatment accordingly. Of the biomarkers currently available, anti-Müllerian hormone (AMH) has been identified as the best tool for individualised gonadotrophin dosing. AMH can also be used to drive evidence-based decisions in the choice of gonadotrophin treatment. Dr Alper presented results from the MEGASET HR trial, which investigated highly purified human menopausal gonadotrophin (HP-hMG) in patients identified via their AMH levels as potential high responders. Dr Havelock then demonstrated how AMH, along with body weight, has allowed for the development of the first dosing algorithm for tailoring treatment with follitropin delta, which has been validated in randomised controlled trials (RCT). Finally, the symposium closed with Prof Fauser concluding that, using the biomarker AMH, it is now possible to personalise not only the dose of gonadotrophin but also the choice of gonadotrophin treatment, representing important first steps in truly individualising OS.

show abstract

The Evolution of Assisted Reproductive Technologies: A Modern Approach to Ovarian Stimulation

Whitehouse¹

2018

EMJ Repro Health

View full text Add to dashboard Cite

show abstract

Assisted Reproductive Technologies Across a Heterogeneous Patient Population

Charlwood¹

2019

EMJ Repro Health

View full text Add to dashboard Cite

With individualised treatment becoming an increasingly relevant topic in reproductive medicine, this symposium discussed how new and existing evidence can support a more patient-centric approach to fertility treatment. Co-Chair Prof Filicori opened the symposium by welcoming delegates and taking a moment to reflect on some of the key milestones in fertility treatment over the past few decades, including approaches that are currently being used to facilitate an individualised approach to controlled ovarian stimulation (OS). Prof Baker continued the theme of individualisation by discussing how the use of different data sources, such as randomised controlled trials (RCT), observational studies, and prediction models, could help guide personalised care. Dr Raine-Fenning presented results from the recent MEGASET-HR trial, which compared the efficacy of highly purified human menopausal gonadotrophin (HP-hMG) versus recombinant follicle-stimulating hormone (rFSH)α in patients predicted to be high responders based on their anti-Müllerian hormone (AMH) levels. The results of this study build on the existing evidence for human chorionic gonadotrophin (hCG)-driven luteinising hormone (LH) activity (HP-hMG) and provide exciting and practical insights on tailoring treatment in this subgroup of patients at risk of ovarian hyperstimulation. Dr Wijngaard-Boom then presented new data from the follitropin delta ESTHER clinical trial programme as well as real-world experience from her own clinic in Rotterdam. The real-world data presented showed that individualised follitropin delta dosing based on the approved algorithm delivers a predictable ovarian response, which is consistent with the results from the ESTHER registration trials, thereby offering positive reassurance about the role of follitropin delta in a clinical setting. The symposium was closed by Co-Chair Prof Laven, who concluded that the approaches discussed during the symposium demonstrate how treatment can be individualised based on a patient’s characteristics, and that, if they are not already, fertility experts should be looking to individualise the treatment for each of their own patients.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Fresh Versus Frozen Euploid Blastocyst Transfer Outcomes in Predicted High-Responders: Menopur in GNRH (Gonadotropin Releasing Hormone) Antagonist Single Embryo Transfer - High Responder (Megaset-Hr) Trial Analysis

Cited by 2 publications

References 0 publications

The Evolution of Assisted Reproductive Technologies: A Modern Approach to Ovarian Stimulation

The Evolution of Assisted Reproductive Technologies: A Modern Approach to Ovarian Stimulation

Assisted Reproductive Technologies Across a Heterogeneous Patient Population

Contact Info

Product

Resources

About